Clinical Trials Logo

Postmenopausal clinical trials

View clinical trials related to Postmenopausal.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05544357 Active, not recruiting - Hypertension Clinical Trials

Cardiovascular Adaptations to Resistance Exercise: Effect of Set Configuration on Postmenopausal Women

CARE
Start date: February 3, 2023
Phase: N/A
Study type: Interventional

The main purpose of this project is to analyze the effect of set configuration of resistance exercise on cardiovascular responses and adaptations of postmenopausal women. Additionally, since previous studies have shown that individual´s blood pressure level can influence on the impact of resistance training programs on cardiovascular changes, we aim to contrast acute and chronic changes to resistance training programs in normotensive and hypertensive postmenopausal women.

NCT ID: NCT05352516 Active, not recruiting - Postmenopausal Clinical Trials

A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture

Start date: June 17, 2022
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, international multicentre, parallel-controlled phase III clinical study. The study plans to enroll 478 postmenopausal women with osteoporosis at high risk of fracture, whom will be randomized at 1:1 to either the experiment group (HLX14) or the control group (Prolia®) based on stratification factors (BMI (< 25, 25-30, > 30) and geographic region (Asian or non-Asian)). The study includes screening period (28 days), treatment period (total 546 days, contain treatment period 1: D1-D364, treatment period 2: D365-D546), and an end-of-study visit (D547).

NCT ID: NCT03090997 Active, not recruiting - Insulin Resistance Clinical Trials

Effect of Resveratrol and Vitamin C on Insulin Resistance Among Postmenopausal Women

Start date: February 15, 2018
Phase: N/A
Study type: Interventional

Hormonal and metabolic changes because of postmenopause increase body weight, central abdominal fat, alter lipid profile and insulin resistance, those factors increase the risk up to 60% to develop metabolic syndrome, diabetes and cardiovascular diseases. Because there is no efficient antioxidant therapy in postmenopausal women, this study proposes a therapy with resveratrol and vitamin C to increase the total antioxidant capacity; as well as to decrease insulin resistance and in consequence decreased the risk of diabetes, metabolic syndrome and cardiovascular disease

NCT ID: NCT02860000 Active, not recruiting - Clinical trials for Stage IV Breast Cancer

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

Start date: July 6, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well alisertib with or without fulvestrant works in treating patients with endocrine-resistant breast cancer that has spread to other places in the body. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells or reducing the amount of estrogen made by the body. Giving alisertib with or without fulvestrant may be better in treating patients with breast cancer.